Article
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Journal of gastroenterology - 1 Aug 2017
Ueda Yoshihide, Ikegami Toru, Akamatsu Nobuhisa, Soyama Akihiko, Shinoda Masahiro, Goto Ryoichi, Okajima Hideaki, Yoshizumi Tomoharu, Taketomi Akinobu, Kitagawa Yuko, Eguchi Susumu, Kokudo Norihiro, Uemoto Shinji, Maehara Yoshihiko
Abstract excerpt
BACKGROUND: The optimal therapy for recurrent hepatitis C virus (HCV) infection after liver transplantation has not yet been established. This study aimed to clarify the efficacy and safety of interferon-free therapy with sofosbuvir and ledipasvir without ribavirin for 12 weeks in Japanese patients with HCV genotype 1b infection after living donor liver transplantation. METHODS: A cohort study of living donor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.